Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OMX-0407 |
Synonyms | |
Therapy Description |
OMX-0407 inhibits salt-inducible kinase 3 (SIK3), potentially leading to tumor cell death, enhanced antitumor immune response, and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 953, Cancer Res (2022) 82 (12_Supplement): 3708). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OMX-0407 | OMX 0407|OMX0407 | OMX-0407 inhibits salt-inducible kinase 3 (SIK3), potentially leading to tumor cell death, enhanced antitumor immune response, and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 953, Cancer Res (2022) 82 (12_Supplement): 3708). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05826600 | Phase I | OMX-0407 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | Recruiting | ESP | BEL | 0 |